Using Pharmaceutical Meta-Analytical Screening (PMAS) for Personalized Microbiome Solution

• Considerations for live-biotherapeutic development and applicability: reviewing microbiota variation, biomarkers, and metabolites.
• Integrating a personalization approach to therapeutic discovery, linking clinical trial outcomes with in-vitro results obtained from the PMAS system.
• How to harness the metabolome to guide the next generation of live-biotherapeutics.

Yosep Ji, Chief Executive Officer, HEM Pharma